FY2024 Earnings Announcement
Committed to Growth & Shareholder Returns

from the beginning

FY2024 Earnings Announcement Committed to Growth & Shareholder Returns

Important Notice

@

Opening Remarks & Business Highlights

Strong Momentum of Growth & Launch Products +14.7% at CER

Takeda’s Global Manufacturing is Centered in U.S., Europe, Japan & Singapore

FY2025 a Pivotal Year as we Prepare for Late-Stage Pipeline Launches

FY2025 Outlook: Final Year of Significant VYVANSE Generic Headwind; Preparing for New Product Launches from Late-Stage Pipeline

Financial Highlights

FY2024 Results: Topline Growth & Strong Cash Flow Generation

FY2024 Results: Delivered Guidance for Revenue & Core O.P. Growth

Efficiency Program Captured ~JPY 200.0B Annualized Savings to Date

FY2024 Revenue: Growth & Launch Products More Than Offset Loss of Exclusivity Impact Including VYVANSE

FY2024 Core Operating Profit: Growth & Launch Products More Than Offset LOE Impact, with OPEX Benefitting from Efficiency Program

FY2024 Reported Operating Profit: Increase Reflects Growth in Core Operating Profit and Lower Impairment Compared to Prior Year

FY2024 Adj. Free Cash Flow: Strong Result of JPY 769.0B Exceeding Forecast

Leverage Ratio Improved by 0.3x in FY2024

Prepaid Syndicated Loans in Q4 with Cash On-hand & Short-term Funding; Short-term Funding to be Re-financed in FY2025

FY2025 Outlook: Final Year of Significant VYVANSE Generic Headwind; Preparing for New Product Launches from Late-Stage Pipeline

Core Revenue Expected to be Broadly Flat at CER, with Growth & Launch Products Momentum Offsetting Carry-over of VYVANSE Generic Impact

Core O.P. Expected to be Broadly Flat at CER, with Efficiency Program Savings, & Investments in R&D, DD&T, and Launch Preparation for Late-stage Pipeline

Reported Operating Profit Forecast Reflects Lower Restructuring Expenses and Conclusion of VYVANSE Amortization in January 2026

Committed to Growth & Shareholder Returns

Pipeline Update

Key FY24 Pipeline Achievements: Advancing Late-Stage Pipeline

FY25 is a Pivotal Year with Three Anticipated Phase 3 Data Readouts

ASCO Plenary Session: Rusfertide Phase 3 VERIFY Study Met Primary and All Four Key Secondary Endpoints in Phlebotomy-Dependent Patients with Polycythemia Vera (PV)

Data Driven Decisions FY24: Continuing Focus on Most Promising Programs

Accelerating the Development of Life Transforming Medicines which have the Potential to Generate Significant Value

Closing Remarks

Foundations in Place to Support New Chapter of Growth for Takeda

Better Health for People, Brighter Future for the World

Q&A SESSION

• Q&A SESSION1

• Q&A SESSION2

• Q&A SESSION3

• Q&A SESSION4

• Q&A SESSION5

• Q&A SESSION6

• Q&A SESSION7

6

Q&A SESSION7

20

6

Q&A SESSION7

• Q&A SESSION8

• Q&A SESSION9

APPENDIX

GASTROENTEROLOGY (GI)

RARE DISEASES

PLASMA-DERIVED THERAPIES

ONCOLOGY

VACCINES

NEUROSCIENCE

Maximizing Potential of Marketed Portfolio Through LCM Expansions

FY24 Report Card for NME Approvals and Indication Expansions

Preparing for an Exciting FY25: Potential Key Phase 3 NME Readouts and Indication Expansions

Consolidated Development Pipeline by Phase

Consolidated Development Pipeline by Phase

Zasocitinib (TAK-279): Best-in-class potential due to high selectivity, once daily oral administration

Continuing Evidence Generation and Indication Expansion

Diverse and Experienced Takeda Executive Team

Glossary of Abbreviations

FINANCIAL APPENDIX

Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations

@

@

FY2024 Reported Results with CER % Change

FY2024 Q4 (Jan-Mar) Reported Results with CER % Change

FY2024 Core Results with CER % Change

FY2024 Q4 (Jan-Mar) Core Results with CER % Change

FY2024 Reconciliation from Reported to Core

FY2024 Q4 (Jan-Mar) Reconciliation from Reported to Core

FY2023 Reconciliation from Reported to Core

FY2023 Q4 (Jan-Mar) Reconciliation from Reported to Core

FY2024 Adjusted Free Cash Flow

FY2024 Adjusted Net Debt to Adjusted EBITDA

FY2023 Adjusted Net Debt to Adjusted EBITDA

FY2024 Net Profit to Adjusted EBITDA Bridge

FY2024 CAPEX, Depreciation and Amortization and Impairment Losses

FY2024 Actual vs. Forecast (Jan. 2025)

FY2025 Full Year Detailed Forecast

FY2025 Full Year Reconciliation from Reported Operating Profit to Core Operating Profit Forecast

FY2025 Full Year FX Rates Assumptions and Currency Sensitivity vs. Forecast

@